KE
Therapeutic Areas
Maze Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MZE001 | APOL1-Mediated Kidney Disease (AMKD) | Phase 2 |
| Undisclosed Program | Pompe Disease (GAA Deficiency) | Preclinical |
Leadership Team at Maze Therapeutics
JC
Jason Coloma, Ph.D.
President and Chief Executive Officer
MB
Mark Boshar
Chief Financial Officer
WH
William H. Rastetter, Ph.D.
Chairman of the Board
HB
Harold Bernstein, M.D., Ph.D.
Chief Medical Officer
MM
Mark Murcko, Ph.D.
Chief Scientific Advisor
CH
Charles Homcy, M.D.
Co-Founder and Board Director
DG
David Goldstein, Ph.D.
Co-Founder and Board Observer
AB
Atul Butte, M.D., Ph.D.
Co-Founder and Board Observer
BZ
Brett Zbar, M.D.
Board Director
SA
Santiago Arroyo, M.D., Ph.D.
Board Director (Partner at SR One)